Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture
I Koneczny, R Herbst - Cells, 2019 - mdpi.com
Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction (NMJ).
Autoantibodies target key molecules at the NMJ, such as the nicotinic acetylcholine receptor …
Autoantibodies target key molecules at the NMJ, such as the nicotinic acetylcholine receptor …
Anti-inflammatory and neuroprotective agents in clinical trials for CNS disease and injury: where do we go from here?
K Mallah, C Couch, DM Borucki, A Toutonji… - Frontiers in …, 2020 - frontiersin.org
Neurological disorders are major contributors to death and disability worldwide. The
pathology of injuries and disease processes includes a cascade of events that often involve …
pathology of injuries and disease processes includes a cascade of events that often involve …
Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models
Complement is involved in developmental synaptic pruning and pathological synapse loss
in Alzheimer's disease. It is posited that C1 binding initiates complement activation on …
in Alzheimer's disease. It is posited that C1 binding initiates complement activation on …
Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease
Complement hyperactivation, angiopathic thrombosis and protein-losing enteropathy
(CHAPLE disease) is a lethal disease caused by genetic loss of the complement regulatory …
(CHAPLE disease) is a lethal disease caused by genetic loss of the complement regulatory …
Clinical efficacy and safety of eculizumab for treating myasthenia gravis
Myasthenia gravis (MG) is an autoimmune disease primarily mediated by acetylcholine
receptor antibodies (AChR-Ab), cellular immune dependence, and complement system …
receptor antibodies (AChR-Ab), cellular immune dependence, and complement system …
Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species
Better understanding of roles of complement in pathology has fuelled an explosion of
interest in complement-targeted therapeutics. The C5-blocking monoclonal antibody (mAb) …
interest in complement-targeted therapeutics. The C5-blocking monoclonal antibody (mAb) …
Second-generation C5 inhibitors for paroxysmal nocturnal hemoglobinuria
B Fattizzo, AG Kulasekararaj - BioDrugs, 2020 - Springer
The C5 targeting monoclonal antibody eculizumab has changed the natural history of
paroxysmal nocturnal hemoglobinuria (PNH) in the last 10 years. However, some unmet …
paroxysmal nocturnal hemoglobinuria (PNH) in the last 10 years. However, some unmet …
TMT-based quantitative proteomic analysis of cumulus cells derived from vitrified porcine immature oocytes following in vitro maturation
BY Jia, DC Xiang, SN Liu, B Zhang, QY Shao… - Theriogenology, 2020 - Elsevier
As the immature oocytes are submitted to cryopreservation, their surrounding cumulus cells
(CCs) will inevitably suffer, which may have some adverse effects on subsequent oocyte …
(CCs) will inevitably suffer, which may have some adverse effects on subsequent oocyte …
[HTML][HTML] Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia
Complement is dysregulated in the brain in Alzheimer's Disease and in mouse models of
Alzheimer's disease. Each of the complement derived effectors, opsonins, anaphylatoxins …
Alzheimer's disease. Each of the complement derived effectors, opsonins, anaphylatoxins …
Characterizing the original anti‐C5 function‐blocking antibody, BB5. 1, for species specificity, mode of action and interactions with C5
The implication of complement in multiple diseases over the last 20 years has fuelled
interest in developing anti‐complement drugs. To date, the focus has been on C5; blocking …
interest in developing anti‐complement drugs. To date, the focus has been on C5; blocking …